Adjuvant Systemic Therapy for Early-Stage Breast Cancer
Author and Disclosure Information [Show]

Zeina Nahleh, MD
Professor of Medicine and Biomedical Sciences, Chief, Division of Hematology-Oncology, Department of Internal Medicine, Co-Director, Garbar Breast Care Center, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, TX

Question 1 of 5

A 55-year-old otherwise healthy postmenopausal woman is diagnosed with a stage IIB T2N1M0 (size 3 × 2.5 × 2 cm) invasive ductal cancer, moderately differentiated. Hormone-receptor testing reveals estrogen-receptor (ER) 95% and progesterone receptor (PR) 20%, and HER2 status is negative. The patient undergoes lumpectomy and axillary lymph node dissection. Three out of 11 axillary lymph nodes are positive for metastatic cancer. Radiation therapy is planned.

Which of the following is the optimal therapeutic option for this patient?

Anastrozole for 5 years

Chemotherapy AC-GT (doxorubicin and cyclophosphamide followed by gemcitabine plus paclitaxel)

Chemotherapy AC-T (doxorubicin and cyclophosphamide followed by paclitaxel) or TC (docetaxel and cyclophosphamide) followed by endocrine therapy

Tamoxifen for 2 to 3 years followed by anastrozole for 3 years

Hospital Physician: Hematology/Oncology. 2015 November;11(6)

This quiz is not accredited for CME.

More from Board Review Questions: Hematology/Oncology


Autoimmune Hemolytic Anemia
Gastrointestinal Stromal Tumors
Testicular Cancer
Management of Advanced Melanoma
Castration-Resistant Prostate Cancer
Transfusion Reactions (part 2)
Transfusion Reactions (part 1)
Plasma Cell Disorders (part 3)
Plasma Cell Disorders (part 2)
Chronic Myeloid Leukemia
Aplastic Anemia
Management of Metastatic Gastric Cancer
Transfusion Medicine
Small Cell Lung Cancer
Management of Colorectal Cancer in Older Adults
Urothelial Carcinoma: Muscle-Invasive and Metastatic Disease
Acute Myeloid Leukemia
Pancreatic Adenocarcinoma: Advanced Unresectable and Metastatic Disease
HER2-Positive Breast Cancer
Aggressive B-Cell Non-Hodgkin Lymphoma
Von Willebrand Disease: Assessment and Diagnostic Testing
Von Willebrand Disease: Clinical Management
Pancreatic Adenocarcinoma: Neoadjuvant and Adjuvant Treatment
Late Pulmonary Complications After Hematopoietic Stem Cell Transplantation
Polycythemia Vera and Essential Thrombocythemia: Current Management
Treatment of Biliary Tract Cancers
Early Pulmonary Complications After Hematopoietic Stem Cell Transplantation
Hairy Cell Leukemia
Genomic Testing in Women with Early-Stage Hormone Receptor–Positive, HER2-Negative Breast Cancer
Immune Thrombocytopenia
Cancer-Related Fatigue
Disseminated Intravascular Coagulation
Advanced Stage and Relapsed/Refractory Hodgkin Lymphoma
Adjuvant Chemotherapy for Colon Cancer
Molecular Markers and Targeted Therapies in the Management of Non-Small Cell Lung Cancer
Metastatic Cutaneous Melanoma: Targeted Therapy and Immunotherapy
Thrombosis in Pregnancy
Locally Advanced Pancreatic Cancer
Early-Stage Hodgkin Lymphoma
Neoadjuvant and Adjuvant Therapy for Gastric Cancer
Hemophilia A and B
Mantle Cell Lymphoma
Soft Tissue Sarcoma
Sickle Cell Disease
Renal Cell Carcinoma
Management of Locally Advanced Rectal Adenocarcinoma
Chronic Myeloid Leukemia
Plasma Cell Disorders
Myelodysplastic Syndromes
Acute and Chronic Graft-versus-Host Disease